Menu Search
Equities

Cue Biopharma Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
1UC:BER

Cue Biopharma Inc

Actions
  • Price (EUR)0.655
  • Today's Change-0.006 / -0.91%
  • Shares traded--
  • 1 Year change-22.02%
  • Beta1.5189
Data delayed at least 15 minutes, as of Jul 15 2025 19:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.

  • Revenue in USD (TTM)7.99m
  • Net income in USD-40.58m
  • Incorporated2014
  • Employees41.00
  • Location
    Cue Biopharma Inc40 Guest StreetBOSTON 02135United StatesUSA
  • Phone+1 (617) 949-2680
  • Fax+1 (302) 655-5049
  • Websitehttps://www.cuebiopharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.